Given that DSBs are highly cytotoxic, PARP inhibitors (PARPi), a prominent class of anticancer drugs, are designed to target tumors with HR deficiency (HRD), such as those harboring BRCA mutations. This evidence concerns the gene PARP1 and hypoparathyroidism-retardation-dysmorphism syndrome.